Floatz logo

pf-00489791

Peripheral Vascular Disease

PfizerSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Peripheral Vascular Disease cohort.

Asset / SponsorPhaseRating
Lipitor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
Telcagepant
Merck Sharp & Dohme LLC
Phase 3BB
TREPROSTINIL PHOSPHATE
United Therapeutics
Phase 3B
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Jose Soberon, MD
Phase 2/3B
Auto-Cd34+ Cells
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 1/2CCC
Rosuvastatin
AstraZeneca
D
Tilmanocept
Massachusetts General Hospital
D
Polycap
St. John's Research Institute
N/AD

Same molecule, other indications

pf-00489791 is also rated in:

postherpetic neuralgiaDormant
B
Indicative ·
57 / 100
View asset →
Raynaud diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →